E-cadherin在乳腺癌诊疗中的研究进展  

Research Advances Regarding E-cadherin in Diagnosis and Treatment of Breast Cancer

作　　者：邵先茹 王竞伟 段秀庆[1] SHAO Xianru;WANG Jingwei;DUAN Xiuqing(Department of Breast Surgery,the First Affiliated Hospital of Harbin Medical University,Harbin 150001,China)

机构地区：[1]哈尔滨医科大学附属第一医院乳腺外科,哈尔滨150001

出　　处：《医学综述》2018年第6期1092-1096,共5页Medical Recapitulate

摘　　要：上皮钙黏素(E-cadherin)是上皮来源肿瘤细胞侵袭、增殖及转移的有效抑制因子,在乳腺癌的发生发展过程中至关重要。乳腺癌患者肿瘤组织中E-cadherin表达降低较为常见,而血清中可溶性E-cadherin却异常增多。肿瘤组织中E-cadherin异常表达的程度与乳腺癌的临床病理因素和分子病理因素有关,在不同的组织学类型或不同分子分型乳腺癌中有显著差异,并且影响患者的预后。E-cadherin的异常表达对于判断乳腺癌类型及预后有重要的作用,其可能是乳腺癌患者有价值的治疗靶点。E-cadherin is an effective inhibitor of tumor cell invasion,proliferation and metastasis of epithelial origin,which is crucial in the development and progression of breast cancer.Decreased expression of E-cadherin is more common in breast cancer patients,whereas serum E-cadherin is abnormally elevated.The abnormal expression of E-cadherin in tumor tissue is related to the clinicopathological factors and molecular pathological factors of breast cancer.There are significant differences in different histological types or different molecular types of breast cancer,and affect the prognosis of the patients.The abnormal expression of E-cadherin plays an important role in judging the type and prognosis of breast cancer,which may be a valuable therapeutic target as well.

关 键 词：乳腺癌 上皮钙黏素 预后 诊疗 

分 类 号：R737.9[医药卫生—肿瘤]